Lisata Therapeutics (LSTA) Competitors $2.19 -0.05 (-2.23%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.20 +0.01 (+0.46%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. IGMS, ASRT, UNCY, CNTX, ARTV, APLT, KLRS, BYSI, IRD, and INCRShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include IGM Biosciences (IGMS), Assertio (ASRT), Unicycive Therapeutics (UNCY), Context Therapeutics (CNTX), Artiva Biotherapeutics (ARTV), Applied Therapeutics (APLT), Kalaris Therapeutics (KLRS), BeyondSpring (BYSI), Opus Genetics (IRD), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors IGM Biosciences Assertio Unicycive Therapeutics Context Therapeutics Artiva Biotherapeutics Applied Therapeutics Kalaris Therapeutics BeyondSpring Opus Genetics InterCure Lisata Therapeutics (NASDAQ:LSTA) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation. Which has higher valuation and earnings, LSTA or IGMS? Lisata Therapeutics has higher earnings, but lower revenue than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M19.18-$19.99M-$2.23-0.98IGM Biosciences$145.05M0.53-$195.79M-$0.90-1.41 Do analysts prefer LSTA or IGMS? Lisata Therapeutics presently has a consensus price target of $23.50, indicating a potential upside of 973.06%. IGM Biosciences has a consensus price target of $4.89, indicating a potential upside of 284.95%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lisata Therapeutics is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00IGM Biosciences 1 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.89 Which has more risk and volatility, LSTA or IGMS? Lisata Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Does the media prefer LSTA or IGMS? In the previous week, Lisata Therapeutics had 2 more articles in the media than IGM Biosciences. MarketBeat recorded 2 mentions for Lisata Therapeutics and 0 mentions for IGM Biosciences. Lisata Therapeutics' average media sentiment score of 1.45 beat IGM Biosciences' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lisata Therapeutics Positive IGM Biosciences Neutral Do institutionals and insiders have more ownership in LSTA or IGMS? 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 57.0% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is LSTA or IGMS more profitable? Lisata Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -36.81%. Lisata Therapeutics' return on equity of -69.68% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -69.68% -59.44% IGM Biosciences -36.81%-93.35%-24.15% SummaryLisata Therapeutics beats IGM Biosciences on 11 of the 16 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.61M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.9821.1774.5225.93Price / Sales19.18480.02549.78198.13Price / CashN/A46.6837.5660.44Price / Book0.639.6112.166.29Net Income-$19.99M-$53.29M$3.28B$270.77M7 Day Performance0.92%0.28%0.87%3.88%1 Month Performance-18.59%5.73%4.96%4.88%1 Year Performance-24.74%10.52%60.74%26.01% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics3.2398 of 5 stars$2.19-2.2%$23.50+973.1%-27.2%$19.61M$1M-0.9830Short Interest ↓Gap DownIGMSIGM Biosciences4.0669 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190ASRTAssertio1.7507 of 5 stars$0.79-4.9%$2.38+199.0%-36.0%$76.43M$124.96M-1.7620UNCYUnicycive Therapeutics1.9644 of 5 stars$4.32+3.1%$60.00+1,288.9%+1.8%$76.30MN/A-1.059CNTXContext Therapeutics3.5202 of 5 stars$0.85+1.2%$5.25+517.8%-61.2%$76.23MN/A-2.367News CoverageShort Interest ↓ARTVArtiva Biotherapeutics3.1254 of 5 stars$3.09-1.9%$17.00+450.2%-76.3%$75.49M$250K0.0081Positive NewsAPLTApplied Therapeutics4.0581 of 5 stars$0.52+5.6%$6.10+1,072.9%-91.4%$74.90M$460K-1.1630Positive NewsGap DownKLRSKalaris Therapeutics1.8786 of 5 stars$4.00-2.0%$3.00-25.0%N/A$74.80MN/A0.00110News CoveragePositive NewsGap DownBYSIBeyondSpringN/A$1.83+6.4%N/A-16.9%$73.80M$1.75M0.0080Positive NewsIRDOpus Genetics2.6892 of 5 stars$1.23+0.8%$7.33+496.2%N/A$73.69M$10.99M-0.6414Positive NewsGap UpINCRInterCure0.7965 of 5 stars$1.61+2.2%N/A-20.3%$73.55M$238.85M0.00350Positive News Related Companies and Tools Related Companies IGM Biosciences Competitors Assertio Competitors Unicycive Therapeutics Competitors Context Therapeutics Competitors Artiva Biotherapeutics Competitors Applied Therapeutics Competitors Kalaris Therapeutics Competitors BeyondSpring Competitors Opus Genetics Competitors InterCure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LSTA Stock Alerts